bioRN Lounge featuring Peter Mark – Thermo Fisher Scientific

‘Common Challenges in the Drug Development Journey’
• Today’s pharma and biotech industry challenges
• Concept of expected net present value of a clinical asset
• Thermo Fisher Scientific’s view on accelerating drug development